Publicaciones en colaboración con investigadores/as de University of Lorraine (2)

2022

  1. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

    The Lancet Diabetes and Endocrinology, Vol. 10, Núm. 1, pp. 35-45

2019

  1. Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes

    JACC: Basic to Translational Science, Vol. 4, Núm. 7, pp. 831-840